Measuring Environmental Tobacco and Cannabis: Pollutants and Exposures (CAN03)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Suzaynn F Schick, Phd
- Phone Number: 4155143535
- Email: suzaynn.schick@ucsf.edu
Study Contact Backup
- Name: Abel Huang, BS
- Phone Number: 415-514-9011
- Email: abel.huang@ucsf.edu
Study Locations
-
-
California
-
San Francisco, California, United States, 94110
- Recruiting
- Zuckerberg San Francisco General Hospital
-
Contact:
- Abel Huang
- Email: Abel.Huang@ucsf.edu
-
Principal Investigator:
- Suzyann Schick, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
-
Adult nonsmokers, aged 21-50, who:
- Are healthy on the basis of medical history
- Have systolic blood pressure <150
- Have diastolic blood pressure <100
- Have BMI between 18.1 and 34.9
- Able to perform moderate exercise,
- Are not exposed to tobacco or cannabis SHS in their daily lives. (Nonsmoking status and low SHS exposure are determined by self-report on the screening questionnaire, salivary cotinine < 10 ng/ml and THC < 50 ng/m and exhaled CO2 below 4 ppm)
Exclusion Criteria:
- Current use of cannabis products, including CBD and edible THC products
- Regular exposure to secondhand tobacco or cannabis smoke
- Positive SARS-CoV-2 antibody test
- Age 18 < or > 50
- Physician diagnosis of asthma, heart disease, hypertension, thyroid disease, diabetes, renal or liver impairment or glaucoma.
- Unstable psychiatric condition (such as current major depression, history of schizophrenia or bipolar disorder) or current use of more than two psychiatric medications
- Systolic blood pressure > 150
- Diastolic blood pressure > 100
- Pregnancy or breastfeeding (by urine hCG and/or history)
- Alcohol or illicit drug dependence within the past 5 years
- BMI > 35 and < 18
- Current illicit drug use (by history or urine test)
- More than 1 pack year smoking history
- Ever a daily marijuana smoker
- Smoked anything within the last 2 months
- Occupational exposure to smoke, dusts OR fumes
- Concurrent participation in another clinical trial
- Unable to communicate in English
- No social security number
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Exposure to secondhand cannabis smoke in public places
The research staff and participants will travel together to a public location by either ride share vehicles, taxis or public transit.
The study will arrange and pay for the transit.
Staff and participants will be exposed to ambient air in public places where cannabis products are being consumed by smoking, vaporizing or dabbing.
Participants will remain in the company of the laboratory staff throughout the exposure.
The exposures will last 0.5-4 hours, depending on the nature and duration of the event.
Staff and participants will travel together back to the laboratory for the post-exposure study measures.
|
This is an environmental exposure performed in public places where people are consuming cannabis.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the concentration of urinary cannabinoid metabolites in health nonsmokers exposed to cannabis smoke and emissions
Time Frame: Baseline (before exposure) and the morning after exposure, up to 22 hours.
|
The concentration of 11-Nor-9-carboxy-THC will be measured in urine with LC/MS-MS.
The LOQ for this assay is 15 pg/ml.
Anticipated changes in concentration are from BLOQ to 0.5-20 ng/ml.
The duration of the exposures will depend on the event or venue at which exposures occur, ranging from 30 minutes to 4 hours.
The investigators will compare the concentration of 11-Nor-9-carboxy-THC in participants' urine before exposure to concentrations in the first void of the morning after the day of exposure.
|
Baseline (before exposure) and the morning after exposure, up to 22 hours.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Suzaynn F Schick, University of California, San Francisco
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- T32IR4867
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.